1. Home
  2. CGEM vs HIPO Comparison

CGEM vs HIPO Comparison

Compare CGEM & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.16

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Hippo Holdings Inc.

HIPO

Hippo Holdings Inc.

HOLD

Current Price

$24.26

Market Cap

737.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
HIPO
Founded
2016
2015
Country
United States
United States
Employees
N/A
540
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
737.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
HIPO
Price
$15.16
$24.26
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
$30.13
$38.67
AVG Volume (30 Days)
998.3K
101.7K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$28.28
Revenue Next Year
$5.20
$22.33
P/E Ratio
N/A
$7.64
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$24.08
52 Week High
$16.74
$38.98

Technical Indicators

Market Signals
Indicator
CGEM
HIPO
Relative Strength Index (RSI) 52.19 31.90
Support Level $11.92 N/A
Resistance Level $16.21 $26.93
Average True Range (ATR) 0.96 0.86
MACD 0.03 -0.16
Stochastic Oscillator 56.07 1.35

Price Performance

Historical Comparison
CGEM
HIPO

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: